USPTO to allow patent for Advaxis’s new vaccine technology

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has been notified that the US Patent and Trademark Office (USPTO) will allow a patent issuance of its application No. 11/785,249 entitled "Antibiotic Resistance Free Vaccines and Methods for Constructing and Using Same."

“The continual expansion of our IP portfolio has helped ensure our preferred-position in the Listeria space”

When issued, this patent will extend the Company's protection of its vaccine technology, which comprises bioengineered alterations in Listeria cell wall synthesis as a method of attenuation. The patent also provides proprietary protection for these compositions, methods and uses to synthesize and deliver various forms of antigen fusion proteins including those based upon listeriolysin O (LLO), ActA or other PEST containing molecules.

Advaxis is currently developing two (2) new vaccines that use this second-generation Listeria backbone to the clinic; one for prostate cancer and another for use against various cancers including breast and brain cancer.

"The continual expansion of our IP portfolio has helped ensure our preferred-position in the Listeria space," said Advaxis Chairman/CEO Thomas A. Moore. "We have designed a series of improvement and innovation layers to our technology platform that can very-well keep our science protected for a very long time."

Source: Advaxis